Repligen | RGEN - Sales Revenues


Repligen reported $204M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Agilent USD 1.84B 37M Mar/2026
Align Technology USD 1.06B 20M Jun/2026
Bio Techne USD 311.4M 15.5M Mar/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Bruker USD 838.5M 15.1M Jun/2026
Charles River Laboratories USD 1000M 4.2M Jun/2026
Danaher USD 6.3B 350M Jun/2026
Dentsply International USD 898M 18M Jun/2026
General Electric Aerospace USD 12.63B 1.03B Jun/2026
Henry Schein USD 3.46B 90M Jun/2026
Illumina USD 1.16B 70M Jun/2026
IQVIA Holdings USD 4.37B 220M Jun/2026
Mettler Toledo International USD 1.03B 82.87M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
Repligen USD 204M 10M Jun/2026
Revvity USD 729.68M 18.68M Jun/2026
Standard Biotools USD 21.1M 2.7M Mar/2026
Thermo Fisher Scientific USD 11.99B 980M Jun/2026
Waters USD 1.64B 370M Jun/2026
West Pharmaceutical Services USD 872.3M 27.4M Jun/2026